Trial Watch—Immunostimulation with cytokines in cancer therapy

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Vacchelli, Erika ^a,b,c,d,e   Aranda, Fernando ^f   Bloy, Norma ^a,b,c,d,e   Buqué, Aitziber ^a,b,c,d,e   Cremer, Isabelle ^a,b,c,d   Eggermont, Alexander ^e   Fridman, Wolf Hervé ^a,b,c,d   Fucikova, Jitka ^g,h   Galon, Jérôme ^a,b,c,d   Spisek, Radek ^g,h   Zitvogel, Laurence ^a,e   Kroemer, Guido ^{a,b,c,d,e,i,j}   Galluzzi, Lorenzo ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g Sotio   (Czech Republic)

^h UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Anticancer vaccines; checkpoint blockers; GM CSF; IL 2; oncolytic virotherapy; Type I interferon

Indexed keywords

EID: 84959386440     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1115942     Document Type: Article

References (158)

1. C.M.Tato, D.J.Cua. SnapShot: Cytokines I. Cell 2008; 132:324.e1; PMID:18243106
2. C.M.Tato, D.J.Cua. SnapShot: Cytokines II. Cell 2008; 132:500; PMID:18267079
3. C.M.Tato, D.J.Cua. SnapShot: Cytokines III. Cell 2008; 132:900; PMID:18329374
4. C.M.Tato, D.J.Cua. SnapShot: Cytokines IV. Cell 2008; 132:1062.e1-2; PMID:18358817
5. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
6. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
7. L.C.Borish, J.W.Steinke. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111:S460-75; PMID:12592293; http://dx.doi.org/10.1067/mai.2003.108
8. J.W.Steinke, L.Borish. 3. Cytokines and chemokines. J Allergy Clin Immunol 2006; 117:S441-5; PMID:16455343; http://dx.doi.org/10.1016/j.jaci.2005.07.001
9. G.Gruenbacher, O.Nussbaumer, H.Gander, B.Steiner, N.Leonhartsberger, M.Thurnher. Stress-related and homeostatic cytokines regulate Vgamma9Vdelta2 T-cell surveillance of mevalonate metabolism. Oncoimmunology 2014; 3:e953410; PMID:25960933; http://dx.doi.org/10.4161/21624011.2014.953410
10. M.Papatriantafyllou. Cytokines: true to their family name. Nat Rev Immunol 2013; 13:544-5; PMID:23827957; http://dx.doi.org/10.1038/nri3496
11. A.A.Hombach, H.Abken. Targeting two co-operating cytokines efficiently shapes immune responses. Oncoimmunology 2013; 2:e23205; PMID:23802072; http://dx.doi.org/10.4161/onci.23205
12. A.Sada, T.Tumbar. New insights into mechanisms of stem cell daughter fate determination in regenerative tissues. Int Rev Cell Mol Biol 2013; 300:1-50; PMID:23273858; http://dx.doi.org/10.1016/B978-0-12-405210-9.00001-1
13. D.Metcalf. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10:425-34; PMID:20495576; http://dx.doi.org/10.1038/nrc2843
14. G.Neufeld, O.Kessler. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006; 25:373-85; PMID:17006765; http://dx.doi.org/10.1007/s10555-006-9011-5
15. R.Benelli, G.Lorusso, A.Albini, D.M.Noonan. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 2006; 12:3101-15; PMID:16918437; http://dx.doi.org/10.2174/138161206777947461
16. K.Ohlsson, P.Bjork, M.Bergenfeldt, R.Hageman, R.C.Thompson. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-2; PMID:2147233; http://dx.doi.org/10.1038/348550a0
17. K.J.Tracey, Y.Fong, D.G.Hesse, K.R.Manogue, A.T.Lee, G.C.Kuo, S.F.Lowry, A.Cerami. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-4; PMID:3317066; http://dx.doi.org/10.1038/330662a0
18. D.M.Andrews, M.T.Chow, Y.Ma, C.L.Cotterell, S.V.Watt, D.A.Anthony, S.Akira, Y.Iwakura, J.A.Trapani, L.Zitvogel Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin. Immunol Cell Biol 2011; 89:739-46; PMID:21263463; http://dx.doi.org/10.1038/icb.2010.168
19. A.W.Seifert, M.Maden. New insights into vertebrate skin regeneration. Int Rev Cell Mol Biol 2014; 310:129-69; PMID:24725426; http://dx.doi.org/10.1016/B978-0-12-800180-6.00004-9
20. L.Zitvogel, L.Galluzzi, O.Kepp, M.J.Smyth, G.Kroemer. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; http://dx.doi.org/10.1038/nri3845
21. J.Crouse, U.Kalinke, A.Oxenius. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol 2015; 15:231-42; PMID:25790790; http://dx.doi.org/10.1038/nri3806
22. F.McNab, K.Mayer-Barber, A.Sher, A.Wack, A.O’Garra. Type I interferons in infectious disease. Nat Rev Immunol 2015; 15:87-103; PMID:25614319; http://dx.doi.org/10.1038/nri3787
23. A.M.Dudek, A.D.Garg, D.V.Krysko, D.De Ruysscher, P.Agostinis. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev 2013; 24:319-33; PMID:23391812; http://dx.doi.org/10.1016/j.cytogfr.2013.01.005
24. A.D.Garg, S.Martin, J.Golab, P.Agostinis. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/cdd.2013.48
25. E.B.Golden, D.Frances, I.Pellicciotta, S.Demaria, M.Helen Barcellos-Hoff, S.C.Formenti. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
26. O.Kepp, L.Senovilla, G.Kroemer. Immunogenic cell death inducers as anticancer agents. Oncotarget 2014; 5:5190-1; PMID:25114034; http://dx.doi.org/10.18632/oncotarget.2266
27. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
28. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
29. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
30. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
31. M.M.Gubin, X.Zhang, H.Schuster, E.Caron, J.P.Ward, T.Noguchi, Y.Ivanova, J.Hundal, C.D.Arthur, W.J.Krebber Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577-81; PMID:25428507; http://dx.doi.org/10.1038/nature13988
32. A.Snyder, V.Makarov, T.Merghoub, J.Yuan, J.M.Zaretsky, A.Desrichard, L.A.Walsh, M.A.Postow, P.Wong, T.S.Ho Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
33. S.Negrier, B.Escudier, C.Lasset, J.Y.Douillard, J.Savary, C.Chevreau, A.Ravaud, A.Mercatello, J.Peny, M.Mousseau Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998; 338:1272-8; PMID:9562581; http://dx.doi.org/10.1056/NEJM199804303381805
34. H.Tsao, M.B.Atkins, A.J.Sober. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012; PMID:15342808; http://dx.doi.org/10.1056/NEJMra041245
35. A.M.Eggermont, A.Spatz, C.Robert. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
36. M.Arellano, S.Lonial. Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2008; 2:13-27; PMID:19707424; http://dx.doi.org/10.2147/BTT.S1355
37. H.J.Khoury, F.R.Loberiza, Jr., O.Ringden, A.J.Barrett, B.J.Bolwell, J.Y.Cahn, R.E.Champlin, R.P.Gale, G.A.Hale, A.Urbano-Ispizua Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107:1712-6; PMID:16239431; http://dx.doi.org/10.1182/blood-2005-07-2661
38. C.Sebban, A.Lefranc, L.Perrier, P.Moreau, D.Espinouse, A.Schmidt, L.Kammoun, H.Ghesquieres, C.Ferlay, J.O.Bay A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 2012; 48:713-20; PMID:22248711; http://dx.doi.org/10.1016/j.ejca.2011.12.016
39. C.Hosing. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012; 904:37-47; PMID:22890920; http://dx.doi.org/10.1007/978-1-61779-943-3_3
40. T.Demirer, M.Ayli, M.Ozcan, N.Gunel, R.Haznedar, M.Dagli, T.Fen, Y.Genc, S.Dincer, O.Arslan Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116:468-74; PMID:11841454; http://dx.doi.org/10.1046/j.1365-2141.2002.03264.x
41. A.Naeim, H.J.Henk, L.Becker, V.Chia, S.Badre, X.Li, R.Deeter. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013; 13:11; PMID:23298389; http://dx.doi.org/10.1186/1471-2407-13-11
42. K.K.Chan, E.Siu, M.D.Krahn, K.Imrie, S.M.Alibhai. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol 2012; 30:1064-71; PMID:22393098; http://dx.doi.org/10.1200/JCO.2011.36.8647
43. T.Pabst, E.Vellenga, W.van Putten, H.C.Schouten, C.Graux, M.C.Vekemans, B.Biemond, P.Sonneveld, J.Passweg, L.Verdonck Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119:5367-73; PMID:22422824; http://dx.doi.org/10.1182/blood-2011-11-389841
44. J.P.Deroose, A.M.Eggermont, A.N.van Geel, J.W.Burger, M.A.den Bakker, J.H.de Wilt, C.Verhoef. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29:4036-44; PMID:21931039; http://dx.doi.org/10.1200/JCO.2011.35.6618
45. J.P.Deroose, A.M.Eggermont, A.N.van Geel, J.H.de Wilt, J.W.Burger, C.Verhoef. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012; 19:627-35; PMID:21879272; http://dx.doi.org/10.1245/s10434-011-2030-7
46. J.P.Deroose, D.J.Grunhagen, A.N.van Geel, J.H.de Wilt, A.M.Eggermont, C.Verhoef. Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg 2011; 98:1573-80; PMID:21739427; http://dx.doi.org/10.1002/bjs.7621
47. A.M.Eggermont. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Gan To Kagaku Ryoho 1996; 23:1357-70; PMID:8854755
48. A.M.Eggermont, H.Schraffordt Koops, J.M.Klausner, B.B.Kroon, P.M.Schlag, D.Lienard, A.N.van Geel, H.J.Hoekstra, I.Meller, O.E.Nieweg Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-64; discussion 64-5; http://dx.doi.org/10.1097/00000658-199612000-00011; PMID:8968230
49. A.M.Eggermont, H.Schraffordt Koops, J.M.Klausner, P.M.Schlag, B.B.Kroon, G.Ben-Ari, F.J.Lejeune. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res 1997; 91:189-203; PMID:9286497; http://dx.doi.org/10.1007/978-1-4615-6121-7_13
50. A.M.Eggermont, H.Schraffordt Koops, D.Lienard, B.B.Kroon, A.N.van Geel, H.J.Hoekstra, F.J.Lejeune. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-65; PMID:8874324
51. S.T.Beug, E.C.LaCasse, R.G.Korneluk. Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncoimmunology 2014; 3:e28541; PMID:25050221; http://dx.doi.org/10.4161/onci.28541
52. A.M.Eggermont, S.Suciu, A.Testori, M.Santinami, W.H.Kruit, J.Marsden, C.J.Punt, F.Salès, R.Dummer, C.Robert Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30:3810-8; PMID:23008300; http://dx.doi.org/10.1200/JCO.2011.41.3799
53. D.J.Grunhagen, F.Brunstein, T.L.ten Hagen, A.N.van Geel, J.H.de Wilt, A.M.Eggermont. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004; 120:65-79; PMID:15217218; http://dx.doi.org/10.1007/1-4020-7856-0_4
54. N.H.Trabulsi, L.Patakfalvi, M.O.Nassif, R.E.Turcotte, A.Nichols, A.N.Meguerditchian. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 2012; 106:921-8; PMID:22806575; http://dx.doi.org/10.1002/jso.23200
55. D.J.Grunhagen, J.H.de Wilt, T.L.ten Hagen, A.M.Eggermont. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3:94-103; PMID:16462850; http://dx.doi.org/10.1038/ncponc0426
56. M.B.Atkins, M.T.Lotze, J.P.Dutcher, R.I.Fisher, G.Weiss, K.Margolin, J.Abrams, M.Sznol, D.Parkinson, M.Hawkins High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16; PMID:10561265
57. G.A.Fyfe, R.I.Fisher, S.A.Rosenberg, M.Sznol, D.R.Parkinson, A.C.Louie. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-1; PMID:8708739
58. G.Fyfe, R.I.Fisher, S.A.Rosenberg, M.Sznol, D.R.Parkinson, A.C.Louie. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-96; PMID:7884429
59. A.Hauschild. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? Curr Oncol 2009; 16:3-6; PMID:19526078; http://dx.doi.org/10.3747/co.v16i3.447
60. B.Anger, F.Porzsolt, R.Leichtle, B.Heinze, C.Bartram, H.Heimpel. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989; 58:275-8; PMID:2736308; http://dx.doi.org/10.1007/BF00320165
61. G.Dranoff. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4:11-22; PMID:14708024; http://dx.doi.org/10.1038/nrc1252
62. L.M.Coussens, Z.Werb. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322
63. L.M.Coussens, L.Zitvogel, A.K.Palucka. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227
64. D.Hershman, A.I.Neugut, J.S.Jacobson, J.Wang, W.Y.Tsai, R.McBride, C.L.Bennett, V.R.Grann. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196-205; PMID:17284714; http://dx.doi.org/10.1093/jnci/djk028
65. S.Di Cosimo, G.Ferretti, P.Papaldo, P.Carlini, A.Fabi, E.M.Ruggeri, A.Alimonti, C.Nardoni, F.Cognetti. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women? Ann Oncol 2005; 16:1209-10; PMID:15857847; http://dx.doi.org/10.1093/annonc/mdi201
66. M.V.Relling, J.M.Boyett, J.G.Blanco, S.Raimondi, F.G.Behm, J.T.Sandlund, G.K.Rivera, L.E.Kun, W.E.Evans, C.H.Pui. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3862-7; PMID:12531808; http://dx.doi.org/10.1182/blood-2002-08-2405
67. E.H.Hinchcliffe. Centrosomes and the art of mitotic spindle maintenance. Int Rev Cell Mol Biol 2014; 313:179-217; PMID:25376493; http://dx.doi.org/10.1016/B978-0-12-800177-6.00006-2
68. A.M.Eggermont, S.Suciu, M.Santinami, A.Testori, W.H.Kruit, J.Marsden, C.J.Punt, F.Salès, M.Gore, R.Mackie Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372:117-26; PMID:18620949; http://dx.doi.org/10.1016/S0140-6736(08)61033-8
69. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
70. E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
71. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
72. C.Robert, L.Thomas, I.Bondarenko, S.O’Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
73. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
74. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
75. N.P.Restifo, M.E.Dudley, S.A.Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81; PMID:22437939; http://dx.doi.org/10.1038/nri3191
76. G.Willimsky, U.Protzer, P.Knolle, M.Heikenwalder. Adoptive T-cell therapy to treat liver cancer: is the liver microenvironment key? Oncotarget 2013; 4:1117-8; PMID:23907631; http://dx.doi.org/10.18632/oncotarget.1179
77. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, I.Cremer, P.Erbs, J.M.Limacher, X.Preville, L.Zitvogel Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
78. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
79. O.Donnelly, E.Ilett, T.Kottke, J.Thompson, R.Vile, A.Melcher. Cytokine-enhanced intravenous oncolytic virotherapy. Lancet 2014; 383:S4; http://dx.doi.org/10.1016/S0140-6736(14)60305-6
80. B.D.Lichty, C.J.Breitbach, D.F.Stojdl, J.C.Bell. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770
81. Y.Tong, L.You, H.Liu, L.Li, H.Meng, Q.Qian, W.Qian. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget 2013; 4:860-74; PMID:23765161; http://dx.doi.org/10.18632/oncotarget.1018
82. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
83. D.H.Hamilton, M.T.Litzinger, A.Jales, B.Huang, R.I.Fernando, J.W.Hodge, A.Ardiani, D.Apelian, J.Schlom, C.Palena. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013; 4:1777-90; PMID:24125763; http://dx.doi.org/10.18632/oncotarget.1295
84. L.Senovilla, E.Vacchelli, P.Garcia, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/onci.23803
85. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
86. V.Gabai, F.M.Venanzi, E.Bagashova, O.Rud, F.Mariotti, C.Vullo, G.Catone, M.Y.Sherman, A.Concetti, A.Chursov Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 2014; 5:12803-10; PMID:25296974; http://dx.doi.org/10.18632/oncotarget.2516
87. T.Blankenstein, P.G.Coulie, E.Gilboa, E.M.Jaffee. The determinants of tumour immunogenicity. Nat Rev Cancer 2012; 12:307-13; PMID:22378190; http://dx.doi.org/10.1038/nrc3246
88. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
89. N.Bloy, J.Pol, F.Aranda, A.Eggermont, I.Cremer, W.H.Fridman, J.Fučíková, J.Galon, E.Tartour, R.Spisek Trial Watch: Dendritic cell-based anticancer therapy. Oncoimmunology 2014; 3:e963424; PMID:25941593; http://dx.doi.org/10.4161/21624011.2014.963424
90. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
91. P.J.Tacken, I.J.de Vries, R.Torensma, C.G.Figdor. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173
92. K.Palucka, J.Banchereau. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
93. J.Wang, D.Lin, H.Peng, J.Shao, J.Gu. Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells. Oncotarget 2014; 5:9727-43; PMID:25179302; http://dx.doi.org/10.18632/oncotarget.2359
94. S.W.Huang, J.K.Kao, C.Y.Wu, S.T.Wang, H.C.Lee, S.M.Liang, Y.J.Chen, J.J.Shieh. Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells. Oncotarget 2014; 5:1363-81; PMID:24658058; http://dx.doi.org/10.18632/oncotarget.1734
95. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
96. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
97. S.Rakoff-Nahoum, R.Medzhitov. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57-63; PMID:19052556; http://dx.doi.org/10.1038/nrc2541
98. E.Pietri, D.Andreis, F.Fabbri, C.Menna, A.Schirone, B.Kopf, A.Rocca, D.Amadori, U.De Giorgi. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer. Oncologist 2015; 20:239-40; PMID:25637379; http://dx.doi.org/10.1634/theoncologist.2014-0326
99. K.Kasai, Y.Kooka, Y.Suzuki, A.Suzuki, T.Oikawa, A.Ushio, Y.Kasai, K.Sawara, Y.Miyamoto, K.Oikawa Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced intrahepatic cholangiocarcinoma. Ann Surg Oncol 2014; 21:3638-45; PMID:24817369; http://dx.doi.org/10.1245/s10434-014-3766-7
100. M.Donini, S.Buti, S.Lazzarelli, R.Bozzetti, L.Rivoltini, C.Camisaschi, C.Castelli, A.Bearz, C.Simonelli, G.Lo Re Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Target Oncol 2015; 10:277-86; PMID:25230695; http://dx.doi.org/10.1007/s11523-014-0337-6
101. J.F.Zeidner, D.E.Gladstone, M.Zahurak, W.H.Matsui, C.Gocke, R.J.Jones, B.D.Smith. Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-alpha (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leuk Res 2014; 38:886-90; PMID:25012565; http://dx.doi.org/10.1016/j.leukres.2014.05.012
102. S.Baek, Y.M.Kim, S.B.Kim, C.S.Kim, S.W.Kwon, Y.Kim, H.Kim, H.Lee. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol 2015; 12:87-95; PMID:24976269; http://dx.doi.org/10.1038/cmi.2014.40
103. R.R.Aggarwal, T.M.Beer, V.K.Weinberg, C.Higano, M.E.Taplin, C.J.Ryan, A.M.Lin, J.Alumkal, J.N.Graff, L.T.Nordquist Intermittent chemotherapy as a platform for testing novel agents in patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium randomized phase II trial of intermittent docetaxel with prednisone with or without maintenance GM-CSF. Clin Genitourin Cancer 2015; 13:e191-8; PMID:25557266; http://dx.doi.org/10.1016/j.clgc.2014.12.004
104. C.Catania, M.Maur, R.Berardi, A.Rocca, A.M.Giacomo, G.Spitaleri, C.Masini, C.Pierantoni, R.González-Iglesias, G.Zigon The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adh Migr 2015; 9:14-21; PMID:25562532; http://dx.doi.org/10.4161/19336918.2014.983785
105. E.Elkord, D.J.Burt, A.Sundstedt, O.Nordle, G.Hedlund, R.E.Hawkins. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget 2015; 6:4428-39; PMID:25669986; http://dx.doi.org/10.18632/oncotarget.2922
106. R.Jarvinen, T.Marttila, E.Kaasinen, E.Rintala, S.Aaltomaa, J.Kallio, T.Liukkonen, V.M.Puolakka, M.Seppänen, K.Tuhkanen Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus calmette-guerin (BCG) or alternating BCG and interferon-alpha2b instillations: Prospective randomised finnBladder-4 study. Eur Urol 2015; 68:611-7; PMID:25748117; http://dx.doi.org/10.1016/j.eururo.2015.02.022
107. E.Kimby, B.Ostenstad, P.Brown, H.Hagberg, M.Erlanson, H.Holte, O.Linden, A.S.Johansson, T.Ahlgren, K.Wader Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma 2015; 56:2598-607; PMID:25686644; http://dx.doi.org/10.3109/10428194.2015.1014363
108. A.Ravaud, C.H.Barrios, B.Alekseev, M.H.Tay, S.S.Agarwala, S.Yalcin, C.C.Lin, L.Roman, M.Shkolnik, O.Anak RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2015; 26:1378-84; PMID:25851632; http://dx.doi.org/10.1093/annonc/mdv149
109. J.J.Luke, H.Donahue, M.Nishino, A.Giobbie-Hurder, M.Davis, N.Bailey, P.A.Ott, F.S.Hodi. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res 2015; 3:986-91; PMID:25943535; http://dx.doi.org/10.1158/2326-6066.CIR-15-0066
110. E.B.Golden, A.Chhabra, A.Chachoua, S.Adams, M.Donach, M.Fenton-Kerimian, K.Friedman, F.Ponzo, J.S.Babb, J.Goldberg Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 2015; 16:795-803; PMID:26095785; http://dx.doi.org/10.1016/S1470-2045(15)00054-6
111. L.Song, X.Zhou, X.Li. Phase II trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer. Mol Clin Oncol 2015; 3:865-8; PMID:26171197; http://dx.doi.org/10.3892/mco.2015.571
112. E.M.Dijkgraaf, S.J.Santegoets, A.K.Reyners, R.Goedemans, M.C.Wouters, G.G.Kenter, A.R.van Erkel, M.I.van Poelgeest, H.W.Nijman, J.J.van der Hoeven A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol 2015; 26:2141-9; PMID:26216383; http://dx.doi.org/10.1093/annonc/mdv309
113. M.Eto, Y.Kawano, Y.Hirao, K.Mita, Y.Arai, T.Tsukamoto, K.Hashine, A.Matsubara, T.Fujioka, G.Kimura Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC Cancer 2015; 15:667; PMID:26452347; http://dx.doi.org/10.1186/s12885-015-1675-1
114. K.C.Conlon, E.Lugli, H.C.Welles, S.A.Rosenberg, A.T.Fojo, J.C.Morris, T.A.Fleisher, S.P.Dubois, L.P.Perera, D.M.Stewart Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015; 33:74-82; PMID:25403209; http://dx.doi.org/10.1200/JCO.2014.57.3329
115. L.Galluzzi. New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology 2013; 2:e26084; http://dx.doi.org/10.4161/onci.26084
116. M.Semeraro, L.Galluzzi. Novel insights into the mechanism of action of lenalidomide. Oncoimmunology 2014; 3:e28386; PMID:25340011; http://dx.doi.org/10.4161/onci.28386
117. M.Semeraro, E.Vacchelli, A.Eggermont, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/onci.26494
118. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
119. S.R.Gameiro, M.L.Jammeh, M.M.Wattenberg, K.Y.Tsang, S.Ferrone, J.W.Hodge. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5:403-16; PMID:24480782; http://dx.doi.org/10.18632/oncotarget.1719
120. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; PMID:25941606; http://dx.doi.org/10.4161/21624011.2014.954929
121. P.Mesange, V.Poindessous, M.Sabbah, A.E.Escargueil, A.de Gramont, A.K.Larsen. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 2014; 5:4709-21; PMID:25015210; http://dx.doi.org/10.18632/oncotarget.1671
122. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
123. P.Chen, P.Bonaldo. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol 2013; 301:1-35; PMID:23317816; http://dx.doi.org/10.1016/B978-0-12-407704-1.00001-4
124. C.Giovannini, M.Baglioni, M.Baron Toaldo, C.Ventrucci, S.D’Adamo, M.Cipone, P.Chieco, L.Gramantieri, L.Bolondi. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget 2013; 4:1618-31; PMID:24113128; http://dx.doi.org/10.18632/oncotarget.1221
125. P.Kharaziha, H.De Raeve, C.Fristedt, Q.Li, A.Gruber, P.Johnsson, G.Kokaraki, M.Panzar, E.Laane, A.Osterborg Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res 2012; 72:5348-62; PMID:22952216; http://dx.doi.org/10.1158/0008-5472.CAN-12-0658
126. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
127. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx.doi.org/10.4161/onci.27878
128. E.Vacchelli, L.Senovilla, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
129. B.I.Rini, J.Bellmunt, J.Clancy, K.Wang, A.G.Niethammer, S.Hariharan, B.Escudier. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014; 32:752-9; PMID:24297945; http://dx.doi.org/10.1200/JCO.2013.50.5305
130. Q.Cai, Y.Chen, D.Zou, L.Zhang, M.Badillo, S.Zhou, E.Lopez, W.Jiang, H.Huang, T.Lin Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget 2014; 5:7368-80; PMID:25228589; http://dx.doi.org/10.18632/oncotarget.2255
131. J.Y.Wagner, K.Schwarz, S.Schreiber, B.Schmidt, H.J.Wester, M.Schwaiger, C.Peschel, C.von Schilling, K.Scheidhauer, U.Keller. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival. Oncotarget 2013; 4:899-910; PMID:23765188; http://dx.doi.org/10.18632/oncotarget.1037
132. M.S.Park, B.R.Kim, S.M.Dong, S.H.Lee, D.Y.Kim, S.B.Rho. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1alpha expression. Oncotarget 2014; 5:4935-44; PMID:24952732; http://dx.doi.org/10.18632/oncotarget.2064
133. M.V.Blagosklonny. Immunosuppressants in cancer prevention and therapy. Oncoimmunology 2013; 2:e26961; PMID:24575379; http://dx.doi.org/10.4161/onci.26961
134. A.Pezzolo, D.Marimpietri, L.Raffaghello, C.Cocco, A.Pistorio, C.Gambini, M.Cilli, A.Horenstein, F.Malavasi, V.Pistoia. Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget 2014; 5:10368-81; PMID:25362644; http://dx.doi.org/10.18632/oncotarget.2015
135. V.Finisguerra, G.Di Conza, M.Di Matteo, J.Serneels, S.Costa, A.A.Thompson, E.Wauters, S.Walmsley, H.Prenen, Z.Granot MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015; 522:349-53; PMID:25985180; http://dx.doi.org/10.1038/nature14407
136. A.Marcais, J.Cherfils-Vicini, C.Viant, S.Degouve, S.Viel, A.Fenis, J.Rabilloud, K.Mayol, A.Tavares, J.Bienvenu The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol 2014; 15:749-57; PMID:24973821; http://dx.doi.org/10.1038/ni.2936
137. T.O’Sullivan, R.Saddawi-Konefka, E.Gross, M.Tran, S.P.Mayfield, H.Ikeda, J.D.Bui. Interleukin-17D mediates tumor rejection through recruitment of natural killer cells. Cell Rep 2014; 7:989-98; PMID:24794441; http://dx.doi.org/10.1016/j.celrep.2014.03.073
138. E.F.Zhu, S.A.Gai, C.F.Opel, B.H.Kwan, R.Surana, M.C.Mihm, M.J.Kauke, K.D.Moynihan, A.Angelini, R.T.Williams Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 2015; 27:489-501; PMID:25873172; http://dx.doi.org/10.1016/j.ccell.2015.03.004
139. B.Ruffell, D.Chang-Strachan, V.Chan, A.Rosenbusch, C.M.Ho, N.Pryer, D.Daniel, E.S.Hwang, H.S.Rugo, L.M.Coussens. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26:623-37; PMID:25446896; http://dx.doi.org/10.1016/j.ccell.2014.09.006
140. J.Hou, Y.Zhou, Y.Zheng, J.Fan, W.Zhou, I.O.Ng, H.Sun, L.Qin, S.Qiu, J.M.Lee Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 2014; 25:49-63; PMID:24360797; http://dx.doi.org/10.1016/j.ccr.2013.11.011
141. O.Litvin, S.Schwartz, Z.Wan, T.Schild, M.Rocco, N.L.Oh, B.J.Chen, N.Goddard, C.Pratilas, D.Pe’er. Interferon alpha/beta enhances the cytotoxic response of MEK inhibition in melanoma. Mol Cell 2015; 57:784-96; PMID:25684207; http://dx.doi.org/10.1016/j.molcel.2014.12.030
142. G.Escobar, D.Moi, A.Ranghetti, P.Ozkal-Baydin, M.L.Squadrito, A.Kajaste-Rudnitski, A.Bondanza, B.Gentner, M.De Palma, R.Mazzieri Genetic engineering of hematopoiesis for targeted IFN-alpha delivery inhibits breast cancer progression. Sci Transl Med 2014; 6:217ra3; PMID:24382895; http://dx.doi.org/10.1126/scitranslmed.3006353
143. T.Bald, J.Landsberg, D.Lopez-Ramos, M.Renn, N.Glodde, P.Jansen, E.Gaffal, J.Steitz, R.Tolba, U.Kalinke Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014; 4:674-87; PMID:24589924; http://dx.doi.org/10.1158/2159-8290.CD-13-0458
144. A.Sistigu, T.Yamazaki, E.Vacchelli, K.Chaba, D.P.Enot, J.Adam, I.Vitale, A.Goubar, E.E.Baracco, C.Remédios Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
145. G.Kroemer, L.Senovilla, L.Galluzzi, F.Andre, L.Zitvogel. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 2015; 21:1128-38; PMID:26444637; http://dx.doi.org/10.1038/nm.3944
146. M.J.Duffy, J.Crown, M.Mullooly. ADAM10 and ADAM17: New players in trastuzumab tesistance. Oncotarget 2014; 5:10963-4; PMID:25460503; http://dx.doi.org/10.18632/oncotarget.2794
147. P.Vici, F.Sperati, M.Maugeri-Sacca, E.Melucci, A.Di Benedetto, L.Di Lauro, L.Pizzuti, D.Sergi, I.Terrenato, L.Esposito p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget 2014; 5:10382-92; PMID:25071015; http://dx.doi.org/10.18632/oncotarget.2060
148. B.D.Choi, I.Pastan, D.D.Bigner, J.H.Sampson. A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system. Oncoimmunology 2013; 2:e23639; PMID:23734318; http://dx.doi.org/10.4161/onci.23639
149. R.B.Walter. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol 2014; 7:317-9; PMID:24617311; http://dx.doi.org/10.1586/17474086.2014.896190
150. M.Turini, P.Chames, P.Bruhns, D.Baty, B.Kerfelec. A FcgammaRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget 2014; 5:5304-19; PMID:24979648; http://dx.doi.org/10.18632/oncotarget.2093
151. G.L.Beatty, R.H.Vonderheide. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7:881-7; PMID:18767939; http://dx.doi.org/10.1586/14760584.7.7.881
152. S.K.Nair, A.Heiser, D.Boczkowski, A.Majumdar, M.Naoe, J.S.Lebkowski, J.Vieweg, E.Gilboa. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
153. Dinutuximab approved for high-risk neuroblastoma. Cancer Discov 2015; 5:OF5; PMID:25851859; http://dx.doi.org/10.1158/2159-8290.CD-NB2015-044
154. J.M.Reichert. Antibodies to watch in 2015. MAbs 2015; 7:1-8; PMID:25484055; http://dx.doi.org/10.4161/19420862.2015.988944
155. D.Zamarin, M.A.Postow. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 2015; 150:23-32; PMID:25583297; http://dx.doi.org/10.1016/j.pharmthera.2015.01.003
156. W.Fang, J.Zhang, S.Hong, J.Zhan, N.Chen, T.Qin, Y.Tang, Y.Zhang, S.Kang, T.Zhou EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5:12189-202; PMID:25361008; http://dx.doi.org/10.18632/oncotarget.2608
157. B.P.Ceresa, J.L.Peterson. Cell and molecular biology of epidermal growth factor receptor. Int Rev Cell Mol Biol 2014; 313:145-78; PMID:25376492; http://dx.doi.org/10.1016/B978-0-12-800177-6.00005-0
158. G.C.Sim, N.Martin-Orozco, L.Jin, Y.Yang, S.Wu, E.Washington, D.Sanders, C.Lacey, Y.Wang, L.Vence IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99-110; PMID:24292706; http://dx.doi.org/10.1172/JCI46266